Borosil Scientific Q4 FY26: Margin expansion and a broader lab portfolio
Borosil Scientific Ltd
BOROSCI
Ask AI
/**Insufficient data: request requires MDX-only output but schema expects string; narrative can be produced, but current instruction says blogpostSummary should be string.*/
Frequently Asked Questions
Consolidated net sales for FY26 were 467.3 crore, as per the FY26 financial overview table.
In Q4 FY26, consolidated net sales were 143.2 crore, EBITDA was 32.4 crore (22.7 percent margin), and PAT was 27.2 crore.
FY26 consolidated category revenues were: Lab Consumables 234.7 crore, Lab Equipment 53.1 crore, Process System 43.2 crore, Pharma Packaging 70.3 crore, Domestic Glassware 60.5 crore, and Others 5.6 crore.
FY26 exceptional items totaled 8.53 crore, including VRS expenses of 6.61 crore and labour code related gratuity and leave encashment provisions of 1.92 crore.
The presentation notes a sales reversal of 1.6 crore in Q4 FY26 as per Ind AS and deferral of certain high-value orders to subsequent quarters, impacting Q4 and FY26 revenues.
The presentation states medium-term goals of achieving revenue CAGR of 12 to 14 percent and improving EBITDA margins, with emphasis on Process Sciences and lab equipment.
The presentation states the company exports to 90 plus countries globally.
Did your stocks survive the war?
See what broke. See what stood.
Live Q4 Earnings Tracker
